Skip to main content
. 2017 Mar 12;2:47–53. doi: 10.1016/j.ibror.2017.03.001

Fig. 2.

Fig. 2

Overall, SOD1 mice treated with CuATSM exhibited delayed onset of paresis (A), and overall neurological disease progression as measured by analysis of ordinal expected score by median age at score (B). Analyzing males separately revealed statistically significant differences (C), however, females when analyzed as a separate cohort only showed a modest trend toward delayed onset of paresis (D).